🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent T-Cell Non-Hodgkin Lymphoma

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD19x22 CAR T Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma NCT05798897Phase 17 sites📍 Duarte📍 Aurora📍 Denver Marker Therapeutics, Inc. · Tests: MT-601 Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site📍 Seattle University of Washington · Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Ther… Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site📍 Shanghai Rong Tao · Tests: Tislelizumab, Zeprumetostat A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype NCT06522737Phase 344 sites📍 Ghent📍 Leuven📍 Prague SecuraBio · Tests: Duvelisib, Gemcitabine, Bendamustine Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites📍 Tucson📍 Tucson📍 Los Angeles National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL NCT05370430Phase 16 sites📍 Duarte📍 Stanford📍 Kansas City PeproMene Bio, Inc. · Tests: BAFFR-CAR T cells CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia NCT06696846Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CD70 CAR-NK CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma NCT06209619Phase 11 site📍 Columbus Nathan Denlinger · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites📍 Los Angeles📍 Palo Alto📍 Aurora Autolus Limited · Tests: AUTO1 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biospecimen Collection, Pomalidomide Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas NCT07883135Phase 21 site📍 Moscow National Research Center for Hematology, Russia · Tests: Glofitamab, Epcoritamab, Polatuzumab Vedotin, Gemcitabine & oxaliplatin, Obinutuzumab Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites📍 La Jolla📍 Boston📍 Rochester AstraZeneca · Tests: AZD5492 Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma NCT07673367Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592Phase 1, Phase 21 site📍 Aurora University of Colorado, Denver · Tests: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL NCT06966154Phase 1, Phase 21 site📍 Shanghai Fudan University · Tests: tislezumab, golidocitinib, Selinexor Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT06810778Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Duvelisib, Venetoclax Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology NCT06378190Phase 1, Phase 28 sites📍 Barcelona📍 L'Hospitalet de Llobregat📍 Madrid Instituto de Investigación Biomédica de Salamanca · Tests: CAR-T cells therapy Amping up With PemJAK NCT07283822Phase 21 site📍 New York Seda S. Tolu · Tests: Ruxolitinib, Pembrolizumab Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites📍 Duarte📍 Chicago📍 New York AIDS Malignancy Consortium · Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL NCT06635330Phase 1, Phase 21 site📍 Tehran Kara Yakhteh Tajhiz Azma Company · Tests: anti-CD19 CAR T cell therapy CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site📍 Prague Institute of Hematology and Blood Transfusion, Czech Republ… · Tests: Autologous CAR19 T lymphocytes NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites📍 Ankara📍 Ankara📍 Ankara Health Institutes of Turkey · Tests: Talikabtagene Autoleucel SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma NCT06122389Phase 31 site📍 Beijing Jiangsu HengRui Medicine Co., Ltd. · Tests: SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies NCT05544968Phase 11 site📍 Milwaukee Medical College of Wisconsin · Tests: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL NCT06854653Phase 215 sites📍 Duarte📍 Irvine📍 New Haven Prescient Therapeutics, Ltd. · Tests: PTX-100
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy